ATAdrien Nzeusseu Toukap

Adrien Nzeusseu Toukap

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adrien Nzeusseu Toukap has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radiographic progression in psoriatic arthritis: head-to-head comparison of the Ratingen score and the Sharp–van der Heijde method

    by Myroslava Kulyk, Silvia Scriffignano, Serge Steinfeld, Adrien Nzeusseu Toukap, Filip van Den Bosch, Rik Joos, Piet Geusens, Rik Lories, Kurt De Vlam, Marthe Van Den Berghe, et al.

    Objectives: To compare the psychometric properties (inter-rater reliability, agreement, responsiveness, and measurement error) of the Psoriatic Arthritis Ratingen Score (PARS) and modified Sharp-van der Heijde (SVDH) methods using the Belgian Psoriatic Arthritis (BePas) cohort. Methods: Radiographs of hands and feet (baseline T0, follow-ups T1, T2) were independently scored by two blinded readers using SVDH (max 528) and PARS (max 360). Statistical analyses included Intraclass Correlation Coefficient (ICC), Bland-Altman analysis, Standardized Response Mean (SRM), and Smallest Detectable Change (SDC). Results: Both methods detected positive mean change, primarily between T0 and T1. Inter-rater reliability for absolute scores was high for both (ICC >0.865; baseline ICC: PARS 0.906, SVDH 0.888). For cumulative change scores (ΔT2–T0), inter-rater reliability was low and very similar for both methods (ICC=0.483 for SVDH and 0.485 for PARS). Both methods showed moderate responsiveness over the cumulative interval (two-reader average SRM: PARS 0.571, SVDH 0.531). For both methods and both readers, mean cumulative change scores were smaller than the corresponding SDC values (PARS: 2.8–3.7% of maximum score; SVDH: 2.8–4.1%), indicating that average progression fell below the threshold of reliable individual-level detection. Bland-Altman analysis showed slightly narrower absolute limits of agreement for PARS in selected comparisons, whereas SVDH showed narrower relative limits after normalization to the maximum possible score. Conclusions: SVDH and PARS showed broadly comparable psychometric performance for PsA damage assessment. Both methods were robust for cross-sectional scoring but showed important limitations in reliably detecting cumulative change in this low-progression cohort. Neither method demonstrated clear superiority.

  • Open Access

    Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis

    by Clément Triaille, Gaëlle Tilman, Tatiana Sokolova, Axelle Loriot, Joelle Marchandise, Stéphanie De Montjoye, Adrien Nzeusseu-Toukap, Laurent Méric de Bellefon, Caroline Bouzin, Christine Galant, et al.

    Objectives Transcriptomic profiling of synovial tissue from patients with early, untreated rheumatoid arthritis (RA) was used to explore the ability of unbiased, data-driven approaches to define clinically relevant subgroups. Methods RNASeq was performed on 74 samples, with disease activity data collected at inclusion. Principal components analysis (PCA) and unsupervised clustering were used to define patient clusters based on expression of the most variable genes, followed by pathway analysis and inference of relative abundance of immune cell subsets. Histological assessment and multiplex immunofluorescence (for CD45, CD68, CD206) were performed on paraffin sections. Results PCA on expression of the (n=894) most variable genes across this series did not divide samples into distinct groups, instead yielding a continuum correlated with baseline disease activity. Two patient clusters (PtC1, n=52; PtC2, n=22) were defined based on expression of these genes. PtC1, with significantly higher disease activity and probability of response to methotrexate therapy, showed upregulation of immune system genes; PtC2 showed upregulation of lipid metabolism genes, described to characterise tissue resident or M2-like macrophages. In keeping with these data, M2-like:M1-like macrophage ratios were inversely correlated with disease activity scores and were associated with lower synovial immune infiltration and the presence of thinner, M2-like macrophage-rich synovial lining layers. Conclusion In this large series of early, untreated RA, we show that the synovial transcriptome closely mirrors clinical disease activity and correlates with synovial inflammation. Intriguingly, lower inflammation and disease activity are associated with higher ratios of M2:M1 macrophages, particularly striking in the synovial lining layer. This may point to a protective role for tissue resident macrophages in RA.


  • Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

    by Penélope Esther Palominos, Daniel G. Fernández-Ávila, Laura C. Coates, Adewale Adebajo, Adrien Nzeusseu Toukap, Ahmed Abogamal, Ari Polachek, Arno W.R. van Kuijk, Francesco Caso, Gabriele de Marco, et al.

    Objective: This literature review aimed to identify the most efficacious current interventions for dactylitis and provide up-to-date scientific evidence to support the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations on the management of psoriatic arthritis.Methods: Original articles published from 2013 to 2020, registered in MEDLINE, Embase, and Cochrane Library, describing interventional trials and reporting dactylitis-related outcomes were included. The 20 members of the GRAPPA dactylitis group were divided into 9 subgroups according to treatment, and members of each group independently extracted data from articles/abstracts corresponding to their group by using a standardized data extraction form.Results: Forty-nine publications were analyzed, representing 40 randomized clinical trials (RCTs) and including 16,752 patients. Dactylitis was assessed as a secondary outcome in 97.5% of these trials and more than 40% of RCTs did not employ a specific dactylitis measure or instrument.Conclusion: The emergence of agents with novel mechanisms of action in recent years, such as interleukin 17 (IL-17), IL-12/23, IL-23, and Janus kinase inhibitors, has significantly expanded the available treatment options for dactylitis. This article points out the lack of consensus regarding dactylitis assessment and the paucity of data concerning the effect of local steroid injections, nonsteroidal antiinflammatory drugs, and conventional disease-modifying antirheumatic drugs. Clinical trials evaluating the effect of these traditional and low-cost medications used to treat dactylitis should be encouraged.


  • Open Access

    POS0259 ULTRASOUND AS AN IMAGING BIOMARKER OF EARLY RESPONSE TO TOCILIZUMAB AND METHOTREXATE IN VERY EARLY RHEUMATOID ARTHRITIS, TOVERA – A LONGITUDINAL STUDY

    by M. Stoenoiu, M. Maruseac, M. Messaoudi, A. Nzeusseu Toukap, E. Naredo

    Background: The combination of methotrexate (MTX) and tocilizumab (TCZ) has been proven to be superior to MTX alone in early rheumatoid arthritis (RA)1 and was able to prevent radiographic progression. Ultrasound (US) has become a valid imaging modality in managing RA. Together with clinical examination, US may allow a comprehensive monitoring of response to therapy. So far, few data are available concerning the early response to TCZ plus MTX in very early RA (VERA). Objectives: In this study we aimed to assess the early US response to TCZ plus MTX in VERA, DMARD-naïve patients. Methods: In this open-label, single-arm study, VERA patients received TCZ (162 mg/week, subcutaneously) and MTX (15-20 mg/week, per os) for 24 weeks as induction therapy, followed by MTX as maintenance therapy. RA was diagnosed according to the 2010 ACR/European league against rheumatism (EULAR) criteria. All patients who fulfilled the inclusion criteria (ClinicalTrials.gov: NCT02837146) underwent blood tests, clinical and ultrasound examinations at the predefined time-points: 0,2,4,8,12,24,32,48,54 weeks (w). Ultrasound examination of 34 joints (elbows, wrists, MCP [1-5, bilateral], PIP ([2-5, bilateral], knees, ankles and MTP [2-5, bilateral]) was performed blindly to clinical data. Gray-scale (GS), power-Doppler (PD) scores, and the global OMERACT-EULAR synovitis score (GLOESS) were assessed in each joint. The sum of individual scores was calculated for 17-joint score (JS) (whole joint set), 10-JS (wrists, MCP, ankles and MTP joints), 12-JS2, and 7-JS3. Results: Forty-four patients (77% women), aged 46.7 ± 12.4 years, completed the 24-week period. Two-thirds (72.7%) were positive for anti-citrullinated protein antibody (ACPA) and 18.2% had bone erosions. At baseline, the mean 28 swollen joints count (28-SJC) was 7.55± 4.5, mean disease activity score (DAS28)-CRP score was 5.2 ± 0.15, mean simplified clinical activity score (SDAI) was 31.4 ± 1.9, mean clinical activity score (CDAI) was 29.1 ± 1.8 and mean health assessments questionnaire (HAQ) score was 1.3 ± 0.1. The C-reactive protein (CRP) decreased significantly at 2w (pConclusion: US scores were able to detect therapeutic response to TCZ plus MTX earlier than clinical scores and may therefore be a promising imaging biomarker. References: [1]Burmester GR et al. Ann Rheum Dis 2017; 76; 1279-1284. [2]Naredo E et al. Arthritis Rheum 2008; 59(4): 515-522. [3]Backhaus M et al. Arthritis Rheum 2009; 61: 1194-1201. Disclosure of Interests: Maria Stoenoiu Grant/research support from: UCB, Roche, Abbvie, MSD, Sanofi, Celgene, Mihaela Maruseac: None declared, Mouna Messaoudi: None declared, Adrien Nzeusseu Toukap Grant/research support from: AbbVie, Eli Lilly, Janssen, UCB, Novartis, Celgene Corporation, Pfizer, Esperanza Naredo Grant/research support from: AbbVie, Roche, BMS, Pfizer, UCB, Eli Lilly, Novartis, Janssen, Celgene


  • Open Access

    FRI0268 REMISSION IN AXIAL SPONDYLOARTHRITIS: IS THERE A DIFFERENCE BETWEEN NSAIDS AND BIOLOGICS IN THE REAL LIFE?

    by C. Baert, C. Mouafo Toukam, T. Sokolova, A. Nzeusseu Toukap

    Background: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (AxSpA) patients have shown that remission in AxSpA and nonradiographic axial SpA patients treated without biologics (BIOL) occurs infrequently (Ref 1, 2). Few are known about remission rate (RR) in daily clinical practice. Objectives: Our aim was to assess the remission rate (RR) in AxSpA patients in Real life, and to compare the RR in AxSpA patients on NSAIDs to RR for those on Biologics (TNFα blockers or IL-17A blockers). Methods: This cross-sectional study reviewed clinical data from a single center (St-Luc university hospitals, UCLouvain, Brussels) from 01/2013 to 03/2019. Last visit available for clinical assessment was evaluated. Disease activity was measured using the Bath Ankylosing Spondylitis disease activity index (BASDAI), and the Ankylosing Spondylitis disease activity score (ASDAS) using the C-reactive protein. Remission was defined as BASDAI < 4 and ASDAS < 1.3. Results: Data from 551 AxSpA patients were reviewed. 353 were men (64.3%). In the entire cohort, 478 BASDAI and 317 ASDAS were recorded. The RR according to the BASDAI was 46.7% (n = 223), and 17.3% for the ASDAS (n = 55). To look for the treatment-related RR, we stratified by the treatment (NSAIDs vs Biologics). We had 285 patients on NSAIDs (177 men, 62.5%) and 266 on BIOL (176 men, 66%). 245 BASDAI were available for NSAIDs and 233 for BIOL. 110 patients on NSAIDs (44.9%) and 113 on BIOL (48.5%) were in remission for BASDAI. Regarding ASDAS (table below), data from 172 patients on NSAIDs and 144 on BIOL were available. Out of them, 27 (15.7%) and 28 (19.4%) were in remission for NSAIDs and BIOL respectively. Chi-square test: p = 0.853. Distribution of ASDAS values in both groups. Conclusion: The real life RR in AxSpA seems to be higher on BIOL, even if compared to NSAIDs, the difference is not significant. However, many patients on NSAIDs achieve the remission. References: [1]Deodhar A. et al. Arthritis Rheumatol 2019 Jul;71(7):1101-1111. 2) Sieper J. et al. Rheumatology (Oxford) 2016 Nov; 55(11): 1946-1953. Disclosure of Interests: Charlotte Baert: None declared, Charlene MOUAFO TOUKAM: None declared, Tatiana Sokolova: None declared, Adrien Nzeusseu Toukap Grant/research support from: AbbVie, Celgene Corporation, Janssen, Pfizer, UCB – grant/research support, Consultant of: AbbVie, Eli Lilly, Janssen, Novartis, UCB – consultant, Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, UCB – advisory board member

  • AB0736 The Bepas Cohort: A Real-Life Multicenter Prospective Cohort of Psoriatic Arthritis in Belgium: Demographics and Baseline Characteristics

    by K. De Vlam, R. Lories, S. Steinfeld, F. Van Den Bosch, A. Nzeusseu Toukap, M. Malaise, V. Taelman, F. Van Bruwaene, M. Van Den Berghe, J. Lenaerts, et al.

    Background Psoriatic arthritis (PsA) is a common form of chronic arthritis with major impact on the physical and psychosocial integrity of the patient. BEPAS (Belgian Epidemiological Psoriatic Arthritis Study) is a large prospective multicenter cohort set up in 17 Belgian rheumatology practices based in secondary and tertiary referral centers (private practice, non-academic and academic hospitals). Objectives (1) To generate a comprehensive database to characterize the clinical presentation and the frequency of the distinct PsA subtypes; (2) to estimate the severity of disease based on disease activity scores and structural damage; (3) to estimate the impact in terms of health-related quality of life of PsA in Belgium and (4) to evaluate progression of structural damage and loss of function in patients with PsA over time. Methods Patients with an existing or a new clinical diagnosis of PsA and fulfilling the CASPAR classification criteria were recruited. All patients gave informed consent. In the prospective study, patients are followed every year during the first 2 years with a possible extension for an additional 5 years. Demographics,clinical parameters, and data about QoL and disability were collected. X-rays of hands and feet are performed every year and axial X-rays every 2 years. Results 461 patients (mean age: 52.79 years (±12.29), male 57%) were recruited from December 2012 to July 2014. N = number of patients with data available. Conclusions This large cohort paints a real-life heterogeneous presentation of PsA in academic and non-academic centers in Belgium and contrast with other cohorts which are mainly academic cohorts. Further data collection will facilitate clinical and outcome studies iabout the impact and natural history of PsA in Belgium. Disclosure of Interest K. De Vlam Grant/research support from: MSD Belgium, R. Lories Grant/research support from: MSD Belgium, S. Steinfeld Grant/research support from: MSD Belgium, F. Van Den Bosch Grant/research support from: MSD Belgium, A. Nzeusseu Toukap Grant/research support from: MSD Belgium, M. Malaise Grant/research support from: MSD Belgium, V. Taelman Grant/research support from: MSD Belgium, F. Van Bruwaene Grant/research support from: MSD Belgium, M. Van Den Berghe Grant/research support from: MSD Belgium, J. Lenaerts Grant/research support from: MSD Belgium, R. Joos Grant/research support from: MSD Belgium, P. Geusens Grant/research support from: MSD Belgium, S. Dall'Armellina Grant/research support from: MSD Belgium, I. Peene Grant/research support from: MSD Belgium, G. De Brabanter Grant/research support from: MSD Belgium, M. Van Den Berghe Grant/research support from: MSD Belgium, J. QU Grant/research support from: MSD Belgium, M. Maertens Grant/research support from: MSD Belgium, H. Leroi Employee of: MSD Belgium